. Author manuscript; available in PMC: 2011 Apr 1.

Published in final edited form as: Cancer Treat Rev. 2010 Jan 6;36(2):142–150. doi: 10.1016/j.ctrv.2009.12.004

Table 2.

New Therapies in AML: Targeting the PI3-K/mTOR Cascade

Target	Compound(s)	Mechanism

PI3-K	CAL-101	Small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3-K (clinicaltrials.gov, NCT00710528)

	PI-103	Small molecule inhibitor of PI3-K and mTOR ¹³⁵.

Akt	Perifosine	Decreases plasma membrane localization of Akt and its phosphorylation ¹³⁶ (clinicaltrials.gov, NCT00391560).

	GSK21110183	Oral small molecule Akt inhibitor (clinicaltrials.gov, NCT00881946).

mTOR	Sirolimus (Rapamycin) Temsirolimus Everolimus (RAD 001) Deforolimus	Directly suppresses mTOR when bound to FKBP12 ⁷⁹, ⁹⁰, ⁹³, ⁹⁶, ¹³⁷.

PIM	SGI-1776	Small molecule inhibitor of tyrosine kinase (clinicaltrials.gov, NCT00848601).